A new cloud-suite of enterprise imaging solutions, the Genesis portfolio, is designed to help improve patient care coordination, reduce operational costs, and maintain robust security standards Allows healthcare providers to more easily store, access, and manage large volumes of medical images from anywhere, anytime Demonstrates GE HealthCare's commitment to increasing the number of cloud-enabled product offerings by 2028, generating recurring revenue through cloud adoption and SaaS-based models, and leading the digital transformation GE HealthCare (NASDAQ:GEHC) today announced its new Genesis solutions, a portfolio of cloud enterprise imaging software-as-a-service (SaaS) solution

Yihao Zhang to retire from GE HealthCare, hands over leadership position to long-time Johnson & Johnson executive, Will Song, a highly knowledgeable and respected leader with a proven track record and decades of industry experience GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song, a Johnson & Johnson veteran for over 20 years, has been named GE HealthCare's new president and CEO, China, and will join the company on April 1, 2025, ahead of leading the region starting July 1 following Yihao's departure. Yihao's planned retirement allowed GE

Freelium, a helium-freei sealed magnet platform in development, aims to dramatically reduce liquid helium usage without sacrificing power efficiency, operational security and clinical performance Leveraging GE HealthCare's proven lightweight, intelligent magnet technology, Freelium will be optimized to seamlessly integrate with future technological advancements and upgrade options, offering flexibility and reliability for imaging departments GE HealthCare (NASDAQ:GEHC) today unveiled Freelium™,ii a next-generation sealed magnet platform, that aims to enable high-quality Magnetic Resonance (MR) imaging with less than 1% of helium used in conventional magnet technology to help support

Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

UBS downgraded GE HealthCare from Neutral to Sell and set a new price target of $74.00 from $84.00 previously

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

10-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

SCHEDULE 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

Fourth Quarter 2024 Revenue growth was 2% year-over-year; Organic revenue growth* was 2% Net income margin was 13.5% versus 7.7% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 18.7% versus 16.1% Diluted earnings per share (EPS) were $1.57 versus $0.88 for the prior year; Adjusted EPS* was $1.45 versus $1.18 Cash flow from operating activities was $913 million versus $1.1 billion for the prior year; Free cash flow* was $811 million versus $956 million Full Year 2024 Revenue growth was 1% year-over-year; Organic revenue growth* was 1% Net income margin was 10.1% versus 8.0% for the prior year; Adjusted EBIT margin* was 16.3% versus 15.1

GE HealthCare (NASDAQ:GEHC) will announce its fourth quarter and full year 2024 financial results before the market opens on Thursday, February 13, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digit

Company updates medium-term framework with progress toward financial goals; increases quarterly cash dividend by approximately 17% GE HealthCare (NASDAQ:GEHC) will host its Investor Day today at Nasdaq MarketSite in New York, NY. The event begins at 8:00 am ET / 7:00 am CT and can be viewed virtually here. Registration is required for in-person attendance. The event will feature presentations from GE HealthCare President and CEO Peter Arduini, GE HealthCare Vice President and CFO Jay Saccaro, and other members of the management team, who will discuss the company's vision and precision care strategy, progress since its spin-off from General Electric Company in 2023, and key growth areas.

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)